Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AS-1763 |
Synonyms | |
Therapy Description |
AS-1763 inhibits BTK, which potentially decreases tumor cell growth (PMID: 34529443). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AS-1763 | AS 1763|AS1763|BN 102|BN-102|BN102 | BTK inhibitor 36 | AS-1763 inhibits BTK, which potentially decreases tumor cell growth (PMID: 34529443). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BTK C481S | diffuse large B-cell lymphoma activated B-cell type | sensitive | AS-1763 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AS-1763 inhibited proliferation of an activated B cell-like (ABC) diffuse large B-cell lymphoma cell line expressing BTK C481S in culture and inhibited tumor growth in a cell line xenograft model (PMID: 34529443). | 34529443 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05602363 | Phase I | AS-1763 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Recruiting | USA | 0 |